Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2G7IP)

Drug Name
E-4177 Drug Info
Synonyms
E-4177; 135070-05-2; CHEMBL71162; 2-[4-[(8-cyclopropyl-5-methyl-2,7,9-triazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)methyl]phenyl]benzoic acid; E4177; VWWMGPCUZVOLLK-UHFFFAOYSA-N; ACMC-20mvn4; AC1L2ZXE; E 4177; SCHEMBL685515; CTK0I0030; DTXSID50159239; BDBM50049212; 3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine; L004970; 4''-(2-Cyclopropyl-7-methyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
131857
CAS Number
CAS 135070-05-2
TTD Drug ID
DM2G7IP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Angiotensin II receptor (AGTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CYT-006-AngQb DMIRSWE Hypertension BA00-BA04 Phase 2 [3]
DA-727 DM9KS1A Hypertension BA00-BA04 Phase 1 [4]
BIBR-363 DMGWFZJ Hypertension BA00-BA04 Discontinued in Phase 2 [5]
FK-739 DM7TLF6 Hypertension BA00-BA04 Discontinued in Phase 2 [6]
ETRX-101 DMRB23N Anemia 3A00-3A9Z Discontinued in Phase 2 [7]
Elisartan potassium DM0XF8J Hypertension BA00-BA04 Discontinued in Phase 2 [8]
ICI-D-8731 DM3R8TX Hypertension BA00-BA04 Discontinued in Phase 2 [9]
CGP-48369 DMY8KO4 Hypertension BA00-BA04 Discontinued in Phase 1 [10]
ICI-D-6888 DMZYA9E Hypertension BA00-BA04 Discontinued in Phase 1 [11]
DuP-532 DM59WQ7 Hypertension BA00-BA04 Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor (AGTR) TTGN1ZA NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002106)
2 Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84.
3 CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
4 WO patent application no. 2009,0880,06, Combined pharmaceutical agent.
5 Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol. 1999 October; 48(4): 594-604.
6 The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. Jpn J Pharmacol. 1993 Nov;63(3):335-43.
7 WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
8 Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995 Apr 15;75(12):793-5.
9 Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7.
10 Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994 May;89(5):2212-8.
11 WO patent application no. 1995,0216,09, Treatment of normotensive glaucoma with angiotensin ii antagonists.
12 DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69.